Human Liver Models Market - Global Market Leaders

Browse 7 market data Tables and 2 Figures spread through 37 Pages and in-depth TOC on "Human Liver Models Market"

https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market-171046468.html

Early buyers will receive 10% customization on reports.

[37 Pages Report] The global human liver models market was valued at USD 1.23 Billion in 2016 and is projected to reach USD 2.56 Billion by 2022, at a CAGR of 13.6% during the forecast period. Base year considered for the report is 2016 and the forecast period considered for this report is 2017–2022.

Objectives of the Study:

• To define, measure, and describe the global human liver model market by type and region
• To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
• To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW

Download the PDF Brochure for More Details@ http://bit.ly/2SAS340

CN Bio held the leading position in the global liver-on-a-chip market in 2016. The company offers its products and services for drug discovery and drug safety programs. To enhance its production capabilities and applications, the company focuses on adopting inorganic strategies such as collaborations and agreements.

Over the last three years, CN Bio has been a part of six such initiatives that helped the company enhance its presence in this market. For instance, in 2017, CN Bio collaborated with AstraZeneca (UK) to validate a new in vitro tool to predict optimized drug dosing regimens for multi-drug therapies. Furthermore, in 2015, CN Bio collaborated with Alnylam Pharmaceuticals (US) to test and develop therapeutics for liver diseases and infections by using LiverChip, CN Bio’s human liver-on-a-chip platform.

The global liver 3D bioprinting market was dominated by Organovo Holdings, Inc. (US). With its broad product portfolio, Organovo Holdings, Inc. held the leadership position in the global 3D bioprinting market for liver in 2016. Its large market share is attributed to its robust 3D bioprinting portfolio. In addition, the company is focusing on various strategies to expand its product offerings and increase its visibility in the 3D bioprinting market. 

In line with this, the company has collaborated with various research organizations and pharmaceutical companies for developing novel products. For instance, in June 2016, Organovo collaborated with the University of California, San Francisco (UCSF) for developing 3D bioprinted tissues, to be used for research on skeletal disease. Similarly, in December 2014, Organovo collaborated with the Yale School of Medicine, Department of Surgery (US) with the aim to develop 3D organ tissues for surgical transplantation research.

You Can Also Get In-Touch with Our Research Experts for More Detailed Information

Target Audience:

• Pharmaceutical and biotechnology companies
• Chemical companies
• Cosmetic product manufacturers, suppliers, and distributors
• Healthcare providers and diagnostic laboratories
• Manufacturers of 3D cell culture products
• Food & beverage manufacturers
• Contract research organizations (CROs)
• Research institutes/universities
• Research and consulting firms
• Venture capitalists

Scope of the Report:

The research report categorizes the human liver model market into the following segments and subsegments:

Human Liver Model Market, by Type

• Liver Organoids
• Liver-on-a-chip
• 2D Models
• Animal Models
• 3D Bioprinting

Human Liver Model Market, by Region

• North America
• Europe
• Asia Pacific
• Rest of the World